| Similar Articles |
|---|
 |
The Motley Fool
May 22, 2007
Mike Havrilla |
An Emergent Opportunity The vaccine developer guided for revenue growth of 10% to 15% for this year. Emergent also has a strong balance sheet, with more than $67 million in cash and investments. Investors, take note.   |
The Motley Fool
March 11, 2011
Brian D. Pacampara |
Emergent BioSolutions Shares Plunged: What You Need to Know Shares of biotechnology company Emergent BioSolutions experienced heavy volatility in early trading after reporting its quarterly results. |
National Defense
June 2011
Eric Beidel |
Industry, Academia Race to Create Drugs Against Biological Warfare On the heels of anthrax comes a string of deadly agents that scientists also fear can be used as weapons and spread with ease. |
National Defense
November 2005
Margaret Davidson |
Biodefense Experts: Vaccines `At a Crossroads' Many of the companies seeking government funds for biodefense work are small firms with no experience in bringing a drug to market. And they face a significant challenge. |
The Motley Fool
July 28, 2008
Dan Dzombak |
3 Stocks Hitting High Notes These stocks are bucking the trend and have just reached all-time highs. Take a look at: Amgen... Wrigley... Emergent BioSolutions... |
Bio-IT World
September 16, 2004
Zachary Zimmerman |
The Dark Side of Project BioShield Despite the uncertainties, an estimated 100 biopharma companies are developing anti-terror technologies. But they should examine both sides of Project BioShield before considering product development. |
The Motley Fool
March 3, 2005
Rich Duprey |
Chiron Back From the Dead British authorities give vaccine manufacturer the go-ahead to restart facility. Investors can breathe a sigh of relief. |
National Defense
June 2007
Breanne Wagner |
Agencies Scramble to Create Vaccine Market Defense and Homeland Security are pursuing disparate vaccination programs to combat different needs for military and civilian populations. |
The Motley Fool
September 2, 2005
Rich Duprey |
Will Flu Vaccine Catch Cold? The CDC says we may have as many as 97 million doses this year, but that's a best-case scenario. This year again, it's Chiron causing the uncertainty. |
The Motley Fool
February 18, 2005
Brian Gorman |
Monsanto Cottons to Emergent Monsanto's second acquisition in less than a month signals an aggressive move into cotton seeds. Investors will no doubt keep a close eye on this one. |
The Motley Fool
October 6, 2004
Rich Duprey |
Chiron Sneezes, Investors Catch Cold British authorities shut down the pharmaceutical's only U.S. flu vaccine manufacturing facility. This may in fact be an opportunity to scoop up a beleaguered stock at fire sale prices. |
